https://www.equinox-group.com/our-take-blog daily 0.75 2026-03-31 https://www.equinox-group.com/our-take-blog/dont-snooze-on-oveporexton-for-narcolepsy-type-1 monthly 0.5 2026-03-31 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6149faaf-b931-4931-b1ab-48ac26fff3a6/oveporexton+Figure.jpg Our Take Blog - Oveporexton Could be a Game-changer for Narcolepsy Type 1 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/problem-with-pmr monthly 0.5 2026-03-05 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/32c7eb08-e98b-4589-b1d0-afbc90b33a33/Kisqali-at-launch.jpg Our Take Blog - The Problem with Primary Market Research - Make it stand out Figure 1: Kisqali at launch https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f58b4214-c7f6-4953-9212-8a00b0ffcd02/Kisqali-OS-benefit.jpg Our Take Blog - The Problem with Primary Market Research - Make it stand out Figure 2: Kisqali update https://www.equinox-group.com/our-take-blog/gene-therapies-for-sickle-cell-disease-expensive-but-worth-it monthly 0.5 2026-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/e0b7dd52-08e1-4523-a8ff-18e5477ab3fb/Casgevy-Figure.jpg Our Take Blog - Gene Therapies for Sickle Cell Disease: Expensive but Worth It - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/keytruda-proc monthly 0.5 2026-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5d88628e-a04a-4c2f-8cb2-044fc8d964d9/Keytruda-paclitaxel-bevacizumab-Figure.jpg Our Take Blog - Keytruda Grabs its 42nd Approval in PD-L1+ PROC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/handling-uncertainty monthly 0.5 2026-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/72550794-49d1-4f16-84ff-c66122768173/no+threat+%283%29.png Our Take Blog - Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D - Make it stand out Figure 1: Launching without a threat https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/e1244070-bc16-4a8e-802b-7fd35cf2cff9/no+threat+%281%29.png Our Take Blog - Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D - Make it stand out Figure 2: Launching with a threat https://www.equinox-group.com/our-take-blog/finding-opportunities monthly 0.5 2026-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/18543269-aab1-48ed-9f86-310a5f247f49/Factors+we+assess.png Our Take Blog - Finding the Best R&D Opportunities - Make it stand out Figure 1: Factors we assess https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/69b410d3-87ea-40b1-a232-04b99cc8fd2e/Indication+Prioritization+CompEnv+vs+UMN.png Our Take Blog - Finding the Best R&D Opportunities - Make it stand out Figure 2: Competitive intensity vs. unmet medical need https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/79f0c619-42c7-4f84-b3b3-b11a1b14d4f0/heat+map+for+website.png Our Take Blog - Finding the Best R&D Opportunities - Make it stand out Figure 3: An introduction to heat maps https://www.equinox-group.com/our-take-blog/drivers-charts monthly 0.5 2026-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/97f594fc-417d-4bc1-9b69-b1d787dfe84d/CI+PNH.PNG Our Take Blog - Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1d33853d-fd2e-4d50-8254-49cde523a207/Contributions+PNH.PNG Our Take Blog - Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH - Make it stand out Soliris 2007 reflects Soliris WAC at launch; all costs inflated to 2025 USD. https://www.equinox-group.com/our-take-blog/measuring-risk-in-rd monthly 0.5 2026-02-13 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0c64df89-8be6-4387-a4c9-8bf62391f167/market_matrix_table.jpg Our Take Blog - Measuring Risk in R&D - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/alecensa-case-study monthly 0.5 2026-02-13 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/44d58614-a51e-453a-a99c-915fc50c0fe3/ACS_Picture1.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/02619c8e-730e-485d-a1dd-940e7ac352e3/Screenshot+2025-11-17+085703.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/be5fbfdd-19f8-487e-984b-075962480e7a/ACS_Picture3.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0cbad2ec-b55a-4afd-b7a9-0bf17d1be570/ACS_Picture4.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a09ce1d4-a144-4fc9-99e5-9e4d97ad0321/ACS_Picture5.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ad15e8d7-e46d-46c8-a2bd-9a4e1972d7c3/ACS_Picture6.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/7bffd806-f88b-4f03-a0e0-b9cb998d9632/ACS_Picture7.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5045e5ca-da55-4924-924c-cdcce8c1e75d/ACS_Picture8.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ff55c377-5893-4eb3-ba8e-20fb3a724a36/ACS_Picture9.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/8c955c20-b8c1-494a-854b-9c75a476d9ab/ACS_Picture10.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5ad4adca-787d-4a70-9649-9567cd0bea0b/ACS_Picture11.png Our Take Blog - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/indication-prioritization monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5c224d76-5740-41fb-b8a8-c9bdff07ca6c/Screenshot+2025-10-30+154345.png Our Take Blog - What indications should we focus on? - Make it stand out Figure 1: Clinical Innovation, Population Size, and Medical Need: A New Drug in 8 Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/207ae8d1-ddc1-4086-b6b3-ff5c79a13d5a/Screenshot+2025-10-30+153908.png Our Take Blog - What indications should we focus on? - Make it stand out Figure 2: Clinical Innovation, Population Size, and Competitive Intensity: A New Drug in 8 Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/17e50149-08dd-4afe-95f6-cb8ebc6efa0e/Screenshot+2025-10-30+164249.png Our Take Blog - What indications should we focus on? - Make it stand out Table 1: The Complete View *Undifferentiated from SOC https://www.equinox-group.com/our-take-blog/suzetrigine monthly 0.5 2025-09-16 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/619ff777-12dd-4997-9813-b723cb89b9c0/Suzetrigine+drivers.jpg Our Take Blog - Journavx, a vast improvement over opioids in moderate acute pain - Make it stand out Figure 1: Drivers of Journavx's Clinical Innovation https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6cad09fd-edb2-494f-a56e-055ed2fe13fc/Screenshot+2025-09-12+142033.png Our Take Blog - Journavx, a vast improvement over opioids in moderate acute pain - Make it stand out Figure 2: Understanding Clinical Innovation https://www.equinox-group.com/our-take-blog/enhertu-first-line-her2 monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/dcec0eaf-7e48-46eb-8e1b-7d52ae9e73f0/Enhertu+regimen+Figure+%281%29.jpg Our Take Blog - Enhertu is poised to dominate first-line HER2+ breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/xolair monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3b97aa0b-a104-4541-8e9c-4937ef90cf6a/Xolair-Figure+JPG.jpg Our Take Blog - Xolair for food allergies: effective therapy at a high price - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/monoclonal-antibodies-alzheimers monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3679d700-56ca-4e97-a85f-e91955dbe2f7/Leqembi-Figure.jpg Our Take Blog - Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/evrysdi-a-potential-game-changer-for-sma-type-1-patients monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3b0a770e-8907-46db-b0cc-d8a44208a7ec/Evrysdi-figure.jpg Our Take Blog - Evrysdi: A Potential Game-Changer for SMA Type 1 Patients - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/03157b8e-b06a-4f19-8dcc-6724f2a8c340/quarterly+revenue+ppt+slide.jpg Our Take Blog - Evrysdi: A Potential Game-Changer for SMA Type 1 Patients - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/9d7147e7-a1a1-4105-b26a-a4ac613ee843/running+total+tx+cost.jpg Our Take Blog - Evrysdi: A Potential Game-Changer for SMA Type 1 Patients - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/car-t-outlook monthly 0.5 2026-02-13 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6647ee5e-f9bc-4199-88fb-a2b0344cb3c7/Yescarta.png Our Take Blog - CAR-T Outlook - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/prospects-for-ulotaront-in-schizophrenia monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f874e9f6-30f8-45a6-ad06-95ddd500558c/Risperidone-vs.-Ulatorant.jpg Our Take Blog - Prospects for ulotaront in schizophrenia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/c81ea71a-8406-48ed-bc32-accb61c17113/Lybalvi-vs.-Ulotaront.jpg Our Take Blog - Prospects for ulotaront in schizophrenia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/enhertu-a-highly-innovative-therapy-for-second-line-metastatic-breast-cancer monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e29f6cc-71bc-4c18-8492-6be7c7c15eb3/Enhertu-vs.-Kadcyla.jpg Our Take Blog - Enhertu shows high clinical innovation in second-line metastatic breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/49499deb-89f2-483d-82e6-7273e1caffe9/Enhertu-vs.-Halaven.jpg Our Take Blog - Enhertu shows high clinical innovation in second-line metastatic breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/weighing-efficacy-vs-tolerability-lenvima-keytruda-in-advanced-ccrcc monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/88a6309b-cff2-4cb3-95cb-edf95035b2e1/Keytruda-and-Lenvima-Figure.jpg Our Take Blog - Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/2386364f-1ab7-49cb-a9d5-9bf702958b01/Final+Key+Lyn+jpeg.jpg Our Take Blog - Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/8745a048-8de1-4ebc-85cf-a1e9b43d1147/Cabo-and-Opdivo-Figure.jpg Our Take Blog - Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/rybrevant-and-exkivity-two-highly-innovative-new-therapies-to-treat-egfr-exon-20-insertion-positive-mnsclc monthly 0.5 2025-11-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6b44bcf0-5798-48d6-a980-4d003b40d1db/amivantamab+figure+jpeg.jpg Our Take Blog - Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/prioritizing-indications-an-analytical-framework monthly 0.5 2025-10-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b7ffc126-40d8-413c-86bd-b78fa5cadd40/Capture3.JPG Our Take Blog - Prioritizing Indications: An Analytical Framework - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/00c91122-2895-43e2-ae58-a3391ea6759c/Capture4.jpg Our Take Blog - Prioritizing Indications: An Analytical Framework - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/trodelvy monthly 0.5 2021-05-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1620308089728-0A9ZVCIO3QTMD7BHWGBJ/drivers.png Our Take Blog - Trodelvy: A New Option for Later Lines TNBC https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1620308186036-GK1C0FI62W5C04AL95OA/bubble+chart.png Our Take Blog - Trodelvy: A New Option for Later Lines TNBC Green bubbles represent drugs with a clinical innovation score greater than 10% (highly innovative drugs) Yellow bubbles represent drugs with a clinical innovation score of 5-10% (moderately innovative drugs) Orange bubbles represent drugs with a clinical innovation score of less than 5% (low innovation drugs) https://www.equinox-group.com/our-take-blog/monjuvi monthly 0.5 2020-10-16 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1602858415786-B5FG8S962GJE8G5V845V/Onco+Drivers.PNG Our Take Blog - Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL https://www.equinox-group.com/our-take-blog/rozlytrek monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1598444849458-PHTY29O9KT7BKINNX65Q/Two+indications.PNG Our Take Blog - Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1598445081902-TFHMINPZGGVNDVP9DZNW/Writ+large+drivers.PNG Our Take Blog - Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1598445626818-156KZB09K8MR6FPOUB6G/brain+mets+drivers.PNG Our Take Blog - Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study https://www.equinox-group.com/our-take-blog/braf-melanoma monthly 0.5 2020-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1595345332905-7N02WD9P1SI1T6WDH2U5/Drivers.JPG Our Take Blog - Pfizer Combo Gains an Edge in BRAF+ Melanoma https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1595345364656-62KRQ4ZOVTQ96ZAJACO9/CvB.JPG Our Take Blog - Pfizer Combo Gains an Edge in BRAF+ Melanoma https://www.equinox-group.com/our-take-blog/trikafta-a-major-step-forward-for-cystic-fibrosis-patients monthly 0.5 2020-07-15 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1594821759112-62CD38C5VHUM6OFSGLR8/Drivers.JPG Our Take Blog - Trikafta: A Major Step Forward for Cystic Fibrosis Patients https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1594821866655-5ATUFANPPKZEJDLTL8TH/RDPC+Table.JPG Our Take Blog - Trikafta: A Major Step Forward for Cystic Fibrosis Patients https://www.equinox-group.com/our-take-blog/nicerecommendations monthly 0.5 2020-07-01 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1591108253996-ZJT8SE2WZUFP2D5Z87SE/2x2.png Our Take Blog - A Reliable Predictor of NICE Recommendation Note: “Innovative” means 5% or higher on Equinox Group’s Clinical Innovation metric https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1591198937774-FVM3ZYGVNIIEZ8AG610Y/bar+chart+corrected.jpg Our Take Blog - A Reliable Predictor of NICE Recommendation https://www.equinox-group.com/our-take-blog/brukinsa-shooting-behind-the-duck-in-rr-mantle-cell-lymphoma monthly 0.5 2026-01-22 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/30bc73b5-73c1-4b62-99bc-f104cd54e516/Brukinsa.png Our Take Blog - Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1590591750039-VTLPTREB4BTF93UYLMVL/image-asset.png Our Take Blog - Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma https://www.equinox-group.com/our-take-blog/lynparza monthly 0.5 2020-07-01 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1588602598572-6SUQILMF1W6CGS61SMBA/Drivers+website.JPG Our Take Blog - Lynparza: Expanding into Prostate Cancer https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1588602635716-SGFI2W37M2UMFAIGL06I/CvB.JPG Our Take Blog - Lynparza: Expanding into Prostate Cancer https://www.equinox-group.com/our-take-blog/keytruda monthly 0.5 2026-02-04 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585841024555-SOSGU5CEWSRAAQW1XKX1/Bubble+chart.JPG Our Take Blog - Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda has described https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585841143960-ARE7L77TWA5LJFRFMDFN/CvB+without+Keytruda+and+arrows.jpg Our Take Blog - Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585843138108-26S1BH4W3NQD7E85H1N5/CvB+with+Keytruda.JPG Our Take Blog - Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda https://www.equinox-group.com/our-take-blog/enhertu monthly 0.5 2020-03-26 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585241189071-9BAAYDVD4DJGHN8FIUUA/drivers+correct.JPG Our Take Blog - Enhertu: A New Leader in Later-Line Breast Cancer https://www.equinox-group.com/our-take-blog/parp-inhibitors-promise-in-new-maintenance-indications monthly 0.5 2020-10-29 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1603990710691-JHS4N4Z5ZNDXC5WFDVYI/Zejula+Updated.JPG Our Take Blog - PARP Inhibitors: Promise in New Maintenance Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1603990728831-UXFULKXF6TXN3K4CJP8A/Lynparza+updated.JPG Our Take Blog - PARP Inhibitors: Promise in New Maintenance Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1583425531368-327EG3JH72LVHS7KU2IM/CvB+CORRECT.JPG Our Take Blog - PARP Inhibitors: Promise in New Maintenance Indications https://www.equinox-group.com/our-take-blog/candidate-observations-to-be-added-to-equinoxs-oncology-normative-pricing-model monthly 0.5 2025-09-15 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b54d2a73-d094-4b3f-8df2-11b910b891c7/now+onco.png Our Take Blog - Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model Pale dots: original observation set Green dots: new candidate observations https://www.equinox-group.com/our-take-blog/tecentriq-and-imfinzi-both-offer-modest-improvements-in-sclc monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1571749786074-S0UBNJ51A4HMVUSHZ4OV/Capture.JPG Our Take Blog - Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1571750028542-6L0X1JDZT3JMWSM6ET4W/CvB.png Our Take Blog - Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC https://www.equinox-group.com/our-take-blog/calquence-the-price-is-right monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1560888869487-KXDKYY85JDFGPR7247UW/Drivers+for+Calquence.PNG Our Take Blog - Calquence: The price is right https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1560890780544-18RUQQ0FPBVZUW5RPORG/Calquence.jpg Our Take Blog - Calquence: The price is right https://www.equinox-group.com/our-take-blog/radicava monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/36320093-d85b-4a48-8559-7184c145a00c/Screenshot+2025-08-06+090503.png Our Take Blog - Radicava: Not Innovative Enough to Sustain Strong Start - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/how-to-price-an-oncology-drug monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1559761834460-NV589J7GQGTCD75693R1/dfsdf.png Our Take Blog - How to Price an Oncology Drug A new drug’s proposed cost (on Y-axis, inverted scale) should align with its promised clinical benefit (on X-axis) to place it in the “cloud” of successful recent launches. https://www.equinox-group.com/our-take-blog/hemlibra monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1553864002874-LGZVPJLBXZV76I6ZLB5Z/Capture.JPG Our Take Blog - Hemlibra: A Strong Leader in Hemophilia A https://www.equinox-group.com/our-take-blog/oral-semaglutide-a-game-changer-in-type-2-diabetes monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1551973852975-I1VKSO7P74C4HR59WCKG/Capture.JPG Our Take Blog - Oral semaglutide: A game changer in type 2 diabetes https://www.equinox-group.com/our-take-blog/tymlos-a-new-force-in-the-osteoporosis-market monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1549483554685-E9ARBRMVN1IDLMP2UEAZ/image-asset.jpeg Our Take Blog - Tymlos: A new force in the osteoporosis market https://www.equinox-group.com/our-take-blog/xeljanz-is-ulcerative-colitis-finally-the-place-for-jaks-to-shine monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1549483141877-TU1NO4EJZJ8VN5NKC0FH/Capture.JPG Our Take Blog - Xeljanz: Is ulcerative colitis finally the place for JAKs to shine? https://www.equinox-group.com/our-take-blog/imbruvica monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547482249237-ISADBOM7X8BLTSVKD5H5/imbruvica+1.JPG Our Take Blog - Imbruvica: Closing the window of opportunity in CLL https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547482533626-D39Z6T9GEDXG1MHIHSRT/Imbruvica+schema.png Our Take Blog - Imbruvica: Closing the window of opportunity in CLL This figure shows the domains of medical need in first line CLL. The gold bars reflect how well ibrutinib satisfies need in each domain. The grey area above the gold bar shows the extent of opportunity for improvement for developmental agents. We derive ibrutinib’s values by transforming clinical data to dimensionless index scores between 0 (no need―e.g., perfect efficacy) and 5 (no satisfaction of need―e.g., no efficacy). The transformation functions are consistent across indications, and domain analyses are built up from detailed sub-analyses. The interpretation for ibrutinib in CLL is that little opportunity remains for improving efficacy, convenience, mortality, or morbidity. The only remaining opportunity for meaningful improvement is in safety/tolerability. The high level of need in the cost domain is driven by high drug cost (which is warranted, given the magnitude of clinical benefit). https://www.equinox-group.com/our-take-blog/keytruda-exceptional-early-results-in-a-small-colorectal-cancer-population monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547486604530-JTLSZHYOQK1BF2GQO1UU/image-asset.jpeg Our Take Blog - Keytruda: Exceptional early results in a small colorectal cancer population https://www.equinox-group.com/our-take-blog/blincyto monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547486806942-QCO9VIJ9DCZER9EUKI9L/image-asset.jpeg Our Take Blog - Blincyto: High price for an undifferentiated drug https://www.equinox-group.com/our-take-blog/multiple-sclerosis monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547484722975-3HTUTL1DGAK7DSKNF9DU/MS+1.JPG Our Take Blog - Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547484761606-4VZ085BFORD5I5TBQ0FE/MS+2.JPG Our Take Blog - Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis https://www.equinox-group.com/our-take-blog/pd-1-inhibitors monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547243356499-CVO19TOQ07C2OFN2T5Y3/opdivo+1.png Our Take Blog - PD-1 Inhibitors: Strong starts in three indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547243382771-FD41EG93E4NCD752JJMI/image-asset.png Our Take Blog - PD-1 Inhibitors: Strong starts in three indications https://www.equinox-group.com/our-take-blog/avastin monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547216717471-CJKDUEUU8WMKPIEQVSVR/avastin.png Our Take Blog - Avastin: One molecule in multiple cancers Note: Bubble size reflects size of the patient population https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547216882097-5U2225L8WZ5LDP0JTQUB/avastin+1.png Our Take Blog - Avastin: One molecule in multiple cancers https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547216928689-OD0V18COH2SAVYTVAUJC/avastin+2.png Our Take Blog - Avastin: One molecule in multiple cancers https://www.equinox-group.com/our-take-blog/jardiance monthly 0.5 2020-10-30 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547482116112-G22F5YRW4ORXZ264R9BS/jardiance.jpg Our Take Blog - Jardiance: New outcomes data in type 2 diabetes https://www.equinox-group.com/our-take-blog/kyprolis monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547487102982-R5CBCCSTNO04O5NFJ1YH/image-asset.jpeg Our Take Blog - Kyprolis: A rapid rise in a crowded market https://www.equinox-group.com/our-take-blog/brintellix-another-me-too-in-major-depression monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547483595212-ACM709QCGYHNFQTD8S90/image-asset.jpeg Our Take Blog - Brintellix: Another "me too" in major depression https://www.equinox-group.com/our-take-blog/pradaxa-stroke-prevention-in-atrial-fibrillation monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547485555815-564EMT00PBZFSJRZ1F17/image-asset.jpeg Our Take Blog - Pradaxa: Stroke prevention in atrial fibrillation https://www.equinox-group.com/our-take-blog/stelara-exceeding-expectations-in-psoriasis monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547485029228-4YGCTGOAAJT5LXDSNUH5/image-asset.jpeg Our Take Blog - Stelara: Exceeding expectations in psoriasis https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547485117506-HKKUYYBAA5HKLJYR85RN/image-asset.jpeg Our Take Blog - Stelara: Exceeding expectations in psoriasis https://www.equinox-group.com/our-take-blog/pristiq-no-innovation-in-major-depressive-disorder monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547486172010-ICQ64LPXUIQ0TE2F7CBC/image-asset.jpeg Our Take Blog - Pristiq: no innovation in major depressive disorder https://www.equinox-group.com/our-take-blog/benlysta monthly 0.5 2020-02-27 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547483949927-F0HMGHS6WV3IIYV5YN8I/image-asset.jpeg Our Take Blog - Benlysta in SLE: A cautionary tale https://www.equinox-group.com/our-take-blog/category/Chronic+Diseases monthly 0.5 https://www.equinox-group.com/our-take-blog/category/Non-Oncology monthly 0.5 https://www.equinox-group.com/our-take-blog/category/Oncology monthly 0.5 https://www.equinox-group.com/our-take-blog/category/R%26D+Insights monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/oveporexton monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lenvima monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Indication+Prioritization monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/risperidone monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/PNH monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/keytr monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/empaveli monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Mektovi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Casgevy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/TNBC monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Approval monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ROS1 monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Carvykti monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Alkermes monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Yescarta monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Alecensa monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Forecasting monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Hemophilia+A monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/emicizumab monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/RCC monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xtandi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Rybrevant monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Trikafta monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Zolgensma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/pancreatic monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/roche monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lyfgenia monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Vertex monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/DLBCL monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ovarian monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Genetix+Biotherapeutics monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/edaravone monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/maintenance+therapy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Oncology monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Kite monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Disease+Area+Strategy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xalkori monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Ovarian+Cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Sunovion monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/soliris monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Exkivity monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Sickle+cell+disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/radicava monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xeljanz monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/NSCLC monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Hematology monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/alexion monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/novartis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Opioid monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Brukinsa monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Eisai monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Unmet+Need monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Aduhelm monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Braftovi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Novartis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Keytruda monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/donanemab monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/MCL monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/NICE monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/pharma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Gilead monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Journavx monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lynparza monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Enhertu monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Platinum-Resistant+Ovarian+Cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Brain+Mets monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Breyanzi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Takeda monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/narcolepsy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ALS monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Evrysdi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/SMA+Type+1 monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/schizophrenia monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xolair monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/piasky monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/fabhalta monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Roche monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lybalvi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ulcerative+colitis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/AstraZeneca monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Zytiga monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Zejula monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Trodelvy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Multiple+Myeloma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Primary+Market+Research monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Insights monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Melanoma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/gene+therapy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/osteoporosis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Oncol monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/R%26D monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Chemotherapy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Genentech monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Pharmaceutical+Insights monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Advate monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Food+allergy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Monjuvi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/rare+disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ACTIVE monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/HRRm monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Eli+Lilly monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/BRCA-mutated monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Bristol+Myers+Squibb monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/riluzole monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Hemlibra monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Spinal+Muscular+Atrophy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Merck monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Spinraza monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Planning+for+the+future monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Clinical+Innovation monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Janssen monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Tymlos monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/lenalidomide monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ultomiris monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/apellis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Rozlytrek monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Incyte monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Pfizer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/breast+cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Daiichi-Sankyo monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Breast+Cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/prostate+cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Biogen monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Equinox monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/drug+pricing monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Alzheimer%27s+Disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/SCD monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Cystic+Fybrosis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Mantle+Cell+Lymphoma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/HER2%2B monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Acute+pain monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Leqembi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ulotaront monthly 0.5 https://www.equinox-group.com/about-us daily 0.75 2026-02-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762285870527-IEPFU3K38AFNF65OJGD0/unsplash-image-3fPXt37X6UQ.jpg About Us https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0f86d9c2-2bfd-4884-b402-44a3a0525758/unsplash-image-5Q07sS54D0Q.jpg About Us - Disease Area Strategy Click here to view our Disease Area Scan and Indication Prioritization Tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762461983655-ZW4QU8X6JA1ZGWOLI77K/unsplash-image-nApaSgkzaxg.jpg About Us - Business Development & Early R&D Click here to view our Disease Target Assessment Framework https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762462006896-P6RWDR5QIBSEVQ5JQN29/unsplash-image-Wb63zqJ5gnE.jpg About Us - Late-Stage Development Click here to view our tools to predict patient share, patient flow, and market access https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b4d6d075-5d93-406c-9140-962ab4d20b93/unsplash-image-5fNmWej4tAA.jpg About Us - Our Unmet Need Framework https://www.equinox-group.com/home daily 1.0 2026-02-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ba35d500-20aa-4e40-b1d0-2a0f20d53251/banner_insight_glow.png Home https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0f86d9c2-2bfd-4884-b402-44a3a0525758/unsplash-image-5Q07sS54D0Q.jpg Home - Disease-area Strategy Explore our Indication Prioritization and Disease-Area Scan tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1769208297741-4GR8TQHNQKN93HS8L6DE/unsplash-image-nApaSgkzaxg.jpg Home - Business Development & Early R&D Take a look at our Signature Disease Target Assessment (DTA) https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1769208235041-ED827QSMU8JAHVQD78FI/unsplash-image-Wb63zqJ5gnE.jpg Home - Late-stage Development Dive into our patient-share forecasting, patient-flow modeling, and market access tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b4d6d075-5d93-406c-9140-962ab4d20b93/unsplash-image-5fNmWej4tAA.jpg Home - Our Unmet need framework Discover the framework at the heart of our analysis and how we use it to predict patient share https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a6a08ddd-5e53-4326-83db-4e3f044d62f7/Screenshot+2025-09-12+105914.png Home - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/how-it-works daily 0.75 2026-01-24 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b4d6d075-5d93-406c-9140-962ab4d20b93/unsplash-image-5fNmWej4tAA.jpg How It Works https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f87c9041-82ea-4cff-8176-c75ba72bc6ce/Factors+we+assess.png How It Works - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0c64df89-8be6-4387-a4c9-8bf62391f167/market_matrix_table.jpg How It Works - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/contact daily 0.75 2026-02-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ba35d500-20aa-4e40-b1d0-2a0f20d53251/banner_insight_glow.png Contact Us https://www.equinox-group.com/what-our-staff-has-to-say daily 0.75 2025-09-26 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1754662232999-38I6L9L33BDPJ4M63TH1/unsplash-image-fVUl6kzIvLg.jpg What Our Staff Has to Say https://www.equinox-group.com/career-opportunities daily 0.75 2026-01-23 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1769208020893-ZEEWN6ZGCWYO3J5ZWZCG/unsplash-image-OQMZwNd3ThU.jpg Career Opportunities https://www.equinox-group.com/our-leadership daily 0.75 2026-01-23 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/e87fe115-15cb-49e6-92cc-5dd4d3af6f77/unsplash-image-ZGjbiukp_-A.jpg Our Leadership https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1545323261197-VHRDWFS3HORSMROUZFSI/walt.jpg Our Leadership - Walter Brooks https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1545163798175-ZKZY910C9CAF4QQUW7XO/AMiller.jpg Our Leadership - Allan Miller https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1545163688392-I8VQ7IUVIX4RGWASW6U4/DAG%252Bwebsite.jpg Our Leadership - David Godolphin https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1545163822353-ALL3IT5B615SCMN3T08R/KC_headshot.jpg Our Leadership - Kaycee Chakrapani https://www.equinox-group.com/chronic-disease daily 0.75 2026-02-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ba35d500-20aa-4e40-b1d0-2a0f20d53251/banner_insight_glow.png Our Take https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/19d68e38-b48a-436f-943d-e0e2f7f64ab6/Screenshot+2025-10-14+143422.png Our Take - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1771341858164-H8ULOJV0FE0Z6BMAW54U/unsplash-image-AAF87btzg9c.jpg Our Take Want to see our work in oncology? Click here. https://www.equinox-group.com/oncology daily 0.75 2026-02-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ba35d500-20aa-4e40-b1d0-2a0f20d53251/banner_insight_glow.png Oncology https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/19d68e38-b48a-436f-943d-e0e2f7f64ab6/Screenshot+2025-10-14+143422.png Oncology https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1771341887683-I85CDFATX8W5WFA27K6Q/unsplash-image-Wz4Mx3JbnzE.jpg Oncology Want to see our work in chronic disease? Click Here. https://www.equinox-group.com/privacy-policy daily 0.75 2026-01-23 https://www.equinox-group.com/recent daily 0.75 2026-02-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ba35d500-20aa-4e40-b1d0-2a0f20d53251/banner_insight_glow.png Our Recent Insights https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1771018218709-YVY4OM2XWMCGO2BW1SKO/unsplash-image-AAF87btzg9c.jpg Our Recent Insights - Oncology Oncology https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1771018084371-72BEVXXK8HT6W12TRAHM/unsplash-image-Wz4Mx3JbnzE.jpg Our Recent Insights - Chronic Disease https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1769459394884-ORRIIDW1VJO1TDJU94M9/unsplash-image-9xHsWmh3m_4.jpg Our Recent Insights - R&D Insights https://www.equinox-group.com/schedule-a-meeting daily 0.75 2026-02-20 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ba35d500-20aa-4e40-b1d0-2a0f20d53251/banner_insight_glow.png Schedule a Meeting https://www.equinox-group.com/late-stage daily 0.75 2026-03-03 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762453992613-6CN5P51S6CF6ZP5Y7NBV/unsplash-image-Wb63zqJ5gnE.jpg Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762369330443-FMCUSQMIM2ER6WMP0WD7/Share+Example.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761935478001-XCSNHEBGXTKOS4CL7NWM/Screenshot+2025-10-31+143034.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762869232433-ELWCYS6FS6U5HCQZZ7U4/Screenshot+2025-11-11+085338.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1772548625504-RKXS3ISHBJ9H2WB8RNJ2/Screenshot+2026-03-02+172059.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761941958781-4EMJ13XXSNLPA9PT2F5T/Screenshot+2025-10-31+161904.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762288113281-2EJ6I154CTUKZRKHYSUI/Screenshot%2B2025-11-04%2B152736.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761942564095-3B6MVXVD0CAUG2GKWC4R/Screenshot+2025-10-31+162910.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762350851519-SW14BDQW8FU7FGR5VRI5/Screenshot+2025-11-05+085356.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761938358852-4WXWDL3FE06G787YZ1IL/Keytruda%252BCvB.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762350903050-QI48AS4DXM9W7ACZ1E39/Specialized%252BTools%252B-%252BRare%252BDisease.png Late Stage Development https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a6a08ddd-5e53-4326-83db-4e3f044d62f7/Screenshot+2025-09-12+105914.png Late Stage Development - Click Here to find out how it works https://www.equinox-group.com/bd-early-rd daily 0.75 2026-03-03 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762454189889-CNW61NT6PDG1H702U6R9/unsplash-image-nApaSgkzaxg.jpg BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761925675720-K3F4HTS55L26G21A5V04/product%2Bx%2Bvs%2By%2Bdrivers.png BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761934668881-CPCRTSUBBAZCAJM5J5N3/UMN.png BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761925330284-924UGMWRNMD4PNQLGSZP/Screenshot+2025-10-31+114202.png BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1768235255562-J3ZU72OHI4BK1K9P6M0E/Untitled+%2834%29.png BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458560814-ISECEXRHF29ZF1J0CX6T/Screenshot+2025-11-05+085356.png BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458580462-SCTMIJ4P6LV2RXWDUCVI/Keytruda+CvB.png BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458851468-L60IMCV5EX2XE4PRAV3H/Specialized%2BTools%2B-%2BRare%2BDisease.png BD & Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a6a08ddd-5e53-4326-83db-4e3f044d62f7/Screenshot+2025-09-12+105914.png BD & Early R&D - Click Here to find out how it works https://www.equinox-group.com/disease-area-strategy daily 0.75 2026-03-03 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762454321626-FMMBU0EO2I9VD7URAVJO/unsplash-image-5Q07sS54D0Q.jpg Disease Area Strategy https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1770646863527-NNYN1XDQ5RDSXBCJQ9F3/Indication+Prioritization+CompEnv+vs+UMN.png Disease Area Strategy https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1770646868104-G6QQT07U4QMGD035PFA2/heat+map+for+website.png Disease Area Strategy https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1770646871571-WF1SPGEZ9F775E4CH6YG/Contributions.png Disease Area Strategy https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761922613809-ANISX12XO3ED8GHX4IY0/Screenshot%2B2025-10-31%2B105128.png Disease Area Strategy https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761925388052-ZC2MFBWQOFFI3AMN9V77/Screenshot%252B2025-10-31%252B092250.png Disease Area Strategy https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761922460286-ATGBP6DPZH62TIDY60FD/indication+prior+CI+UMN+website.png Disease Area Strategy https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a6a08ddd-5e53-4326-83db-4e3f044d62f7/Screenshot+2025-09-12+105914.png Disease Area Strategy - Click Here to find out how it works https://www.equinox-group.com/tools daily 0.75 2026-03-30 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/733a0d28-b132-439b-9db0-aa7445cac833/unsplash-image-774sCXD0dDU.jpg Our Tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0f86d9c2-2bfd-4884-b402-44a3a0525758/unsplash-image-5Q07sS54D0Q.jpg Our Tools - Disease Area Strategy Click here to view our Disease Area Scan and Indication Prioritization Tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762454517920-SPIZSQWY7BABKW5ZWTGT/unsplash-image-nApaSgkzaxg.jpg Our Tools - Business Development & Early R&D Click here to view our Disease Target Assessment Framework https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762454565348-D608JHK68ZJ2B1JUN265/unsplash-image-Wb63zqJ5gnE.jpg Our Tools - Late-Stage Development Click here to view our Competition Module tools to predict patient share, patient flow, and market access https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a6a08ddd-5e53-4326-83db-4e3f044d62f7/Screenshot+2025-09-12+105914.png Our Tools - Click Here to find out how it all works https://www.equinox-group.com/what-on-earth-is-clinical-innovation daily 0.75 2025-11-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0f86d9c2-2bfd-4884-b402-44a3a0525758/unsplash-image-5Q07sS54D0Q.jpg What on earth is Clinical Innovation? - Disease Area Strategy Disease Area Strategy Click here to view our Disease Area Scan and Indication Prioritization Tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1763671858133-6NRLW0ALTCGRIFRGHAAO/unsplash-image-nApaSgkzaxg.jpg What on earth is Clinical Innovation? - Early R&D Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1763671831309-WZC8HLQLNMQ90FD7940B/unsplash-image-Wb63zqJ5gnE.jpg What on earth is Clinical Innovation? - Late-Stage Development Click here to view our Competition Module tools to predict patient share, patient flow, and market access https://www.equinox-group.com/rd-insights daily 0.75 2026-02-13 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1769459444409-M37PXUY7MPHVFZLNWPLO/unsplash-image-9xHsWmh3m_4.jpg R&D https://www.equinox-group.com/dta-ready daily 0.75 2026-03-03 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/d1ff5972-d713-4e29-84aa-3047e3894655/equinox_background_16x9+%281%29.png DTA Ready™